Our results apply to a particular mIDH1 molecular subtype, which harbors concomitant inactivating mutations in TP53 and ATRX, recently classified by the WHO as mIDH1 astrocytomas.77 This genotype was included in all in vitro, ex vivo, and in vivo experiments presented. This evidence concerns the gene ATRX and astrocytoma (excluding glioblastoma).